Official Title
Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia)
Brief Summary

There is a high risk of transmission of COVID-19 to healthcare workers. In a recent cohort, 29% of the patients hospitalized were healthcare workers. Among the WHO's primary strategic objectives for the response to COVID-19, the first was to limit human-to-human transmission, including reducing secondary infections among close contacts and health care workers. Automated oxygen titration, weaning and monitoring (FreeO2 device) may be a solution to reduce the number of interventions of healthcare workers related to oxygen therapy, to reduce complications related to oxygen and to improve monitoring.

Unknown status
Oxygen Toxicity

Other: Standard administration of oxygen flow

The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.
In this group the SpO2 was recorded any time with FreeO2 device - recording mode

Device: Automated oxygen administration - FreeO2

In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)

Eligibility Criteria

Inclusion Criteria:

- Age> 18 years old

- patients with acute respiratory failure related to suspected community acquired
pneumonia (viral and non viral) requiring oxygen therapy < 6 L/min (or FiO2< 0.50) (to
maintain SpO2 between 90 and 94% SpO2) without criteria for immediate intubation or
ICU transfer.

- Patients hospital admission < 72 hours

Exclusion Criteria:

- shock state,

- no SpO2 signal available,

- patient agitation,

- pH < 7.30 (if blood gas available)

- PaCO2 > 50 mmHg, (if blood gas available) or chronic hypercapnia history

- Non invasive respiratory support (NIV, High flow Nasal Therapy (HFNT)) at study

- Withdrawal of life support or palliation as the goal of care

- patients' or next of kin refusal to participate to the study

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
Quebec, Canada

Investigator: Pierre-Alexandre Bouchard
Contact: 418-656-8711

Investigator: Francois Lellouche


François Lellouche
418-656-8711 - 3572

Pierre-Alexandre Bouchard
418-656-8711 - 2712

Francois Lellouche, Principal Investigator

Laval University
NCT Number
MeSH Terms